Ranbaxy Laboratories Limited v. M/S Intas Pharmaceuticals Ltd.

In the high-stakes world of pharmaceuticals, a brand name is more than just a label—it's a lifeline of trust between a company and the patients who depend on its medicines. When two drugmakers launch products with names that sound strikingly similar, the consequences can ripple through pharmacies, hospitals, and homes across the country. This is the story of how the Delhi High Court navigated one such clash, choosing a path of measured caution over the sweeping ban that one party desperately sought.

Ranbaxy Laboratories, an established name in the pharmaceutical industry, found itself in a trademark dispute with Intas Pharmaceuticals. At the heart of the conflict were two drug trademarks: 'NIFTRAN', used by Ranbaxy, and 'NIFTAS', adopted by Intas. Believing that the similarity between the two names could mislead consumers and erode its hard-earned brand equity, Ranbaxy filed a passing off suit against Intas. The plaintiff approached the court seeking an interim injunction—an urgent order to immediately halt Intas from selling under the contested name. The stage was set for a classic showdown over brand identity in the sensitive pharmaceutical sector.

Ranbaxy argued that 'NIFTAS' was deceptively similar to its own mark 'NIFTRAN', and that allowing Intas to continue using the name would cause confusion among doctors, pharmacists, and patients. The plaintiff pushed for a complete stop on sales, emphasizing the potential harm to its reputation and the risk of public deception. Intas, on the other hand, countered that the marks were sufficiently distinct and that an outright ban would be disproportionate. The legal friction centered on a fundamental question: should the court prioritize the plaintiff's claim of likely confusion, or weigh the broader implications of restricting access to a medicinal product?

The Delhi High Court delivered a carefully calibrated ruling. Rather than granting the blanket injunction Ranbaxy sought, the court recognized the need to balance trademark protection against public interest in pharmaceutical products. The defendant, Intas, was directed to maintain complete accounts of all sales and profits derived from the product sold under the 'NIFTAS' mark. Additionally, the court imposed specific restrictions on the types of packaging Intas could use, ensuring that any potential confusion could be tracked and mitigated during the ongoing proceedings. This mixed outcome allowed the litigation to advance while preventing immediate, irreparable harm to either side.

For founders and IP professionals in the pharmaceutical space, this case offers a vital lesson: courts do not always swing the hammer of an immediate injunction, even when trademark similarity is evident. When dealing with essential products like medicines, judges often opt for a middle path—preserving the plaintiff's ability to seek damages through account records while limiting the defendant's freedom just enough to prevent deception. The takeaway is clear: build your brand with distinctive names from the start, and if you find yourself on either side of a passing off dispute, prepare for a process that values caution, accountability, and public welfare over quick wins.